A registration-enabling study of the combination of TRC105 and Nexavar in Hepatocellular Carcinoma (HCC)
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Carotuximab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors TRACON Pharmaceuticals
- 23 Jan 2018 New trial record
- 19 Jan 2018 According to a TRACON Pharmaceuticals media release, the company is planning to discuss this trial with regulatory authorities.